Mineralys Therapeutics, Inc. (MLYS): Operating Income

Annual figures by period end, from SEC filings.

-$170.60M

Year ended 2025-12-31

-$370.79M

Trailing 12 months to 2026-06-30

2022-12-31 Operating Income (USD) 2025-12-31

Period ended	Operating Income	Change YoY	Source filing
2025-12-31	-$170.60M	n/m	2026-03-12, From 2025-01-01
2024-12-31	-$192.40M	n/m	2026-03-12, From 2024-01-01
2023-12-31	-$84.66M	n/m	2025-02-12, From 2023-01-01
2022-12-31	-$31.48M	n/a	2024-03-21, From 2022-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Income	Change YoY
Mineralys Therapeutics, Inc. (MLYS)	2025-12-31	-$170.60M	n/m
Protagonist Therapeutics, Inc (PTGX)	2025-12-31	-$158.13M	n/m
Amarin Corp PLC (AMRN)	2025-12-31	-$50.17M	n/m
Immunome Inc. (IMNM)	2025-12-31	-$224.11M	n/m
Wave Life Sciences, Inc. (WVE)	2025-12-31	-$215.38M	n/m
Nurix Therapeutics, Inc. (NRIX)	2025-11-30	-$285.67M	n/m
Axsome Therapeutics, Inc. (AXSM)	2025-12-31	-$166.76M	n/m
Xenon Pharmaceuticals Inc. (XENE)	2025-12-31	-$373.07M	n/m
Viking Therapeutics, Inc. (VKTX)	2025-12-31	-$393.34M	n/m

Compare MLYS, PTGX, AMRN, IMNM side by side · Screen every company in Pharmaceutical Preparations ↗